logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Late Sep 2016
GALECTIN THERAPEUTICS INC
Top-line data from Phase 2 trial with GR-MD-02
Non-alcoholic steatohepatitis (NASH) with advanced fibrosis
Late 2016
RedHill Biopharma Ltd.
Top-line data Phase 3 study of Bekinda (GUARD study)
Acute gastroenteritis and gastritis
Late 2016
ISIS Pharmaceuticals Inc
Topline data from phase 3 study of ISIS-SMN Rx (ENDEAR)
Spinal muscular atrophy in infants
Late 2016
ISIS Pharmaceuticals Inc
Top line data from the second phase 3 study of ISIS-SMNRx (CHERISH)
Spinal muscular atrophy in children
Late 2016
Biomarin Pharmaceutical Inc.
Results from phase 2 study of Talazoparib (BMN 673) (ABRAZO study)
Locally advanced and/or metastatic breast cancer with germline BRCA mutations
Late 2016
Ultragenyx Pharmaceutical Inc
Interim data from phase 2 study of rhGUS
Patients under five years old with MPS 7
Late 2016
Versartis Inc.
Interim 6-month data from Phase 3 pediatric registration trial of Somavaratan (VELOCITY)
Pediatric growth hormone deficiency
Late 2016
Affimed N.V.
Initial data from phase I trial of AFM11
Non-Hodgkin's lymphoma
Late 2016
BioLineRx Ltd.
Partial results from phase II trial of BL-8040
Novel Stem Cell Mobilization Treatment
Late 2016
Antares Pharma Inc.
File NDA for QuickShot Testosterone
Hypogonadism
Late 2016
Alnylam Pharmaceuticals Inc.
Initial data from phase 1/2 trial of ALN-GO1
Primary Hyperoxaluria Type 1 (PH1)
Late 2016
Mirati Therapeutics, Inc.
Initial data from phase 2 trial of MGCD265 (Glesatinib)
Non-small-cell lung carcinoma (NSCLC)
Late 2016
ProNAi Therapeutics Inc
Interim data from Phase 2 trial of PNT2258 (Brighton)
Richter's transformation
Late 2016
GTX Inc.
Preliminary results from phase 2 trial of Enobosarm
Metastatic or locally advanced, ER+/AR+ breast cancer
Late 2016
La Jolla Pharmaceutical Co
Results from phase 3 trial of LJPC-501 ( ATHOS)
Catecholamine-resistant hypotension
Late 2016
Acceleron Pharma, Inc
Present preliminary results from phase 2 study of Dalantercept (DART)
Renal cell carcinoma
Late 2016
Alnylam Pharmaceuticals Inc.
Initial data from Part C of phase 1 trial of ALN-AS1
Acute hepatic porphyrias
Late 2016
BiondVax Pharmaceuticals Ltd.
Results from phase 2b trial of M-001
Universal flu vaccine
Late 2016
RXi Pharmaceuticals Corp.
Early results from new cohorts of phase 2 trial of RXI-109 (RXI-109-1402)
Hypertrophic scars
Late 2016
Affimed N.V.
Primary endpoint data from phase 2a trial of AFM13
Relapsed/refractory Hodgkin lymphoma
Sep 2016
Amarin Corp Plc
Interim analysis of phase 3 study of Vascepa (REDUCE-IT)
Reduce cardiovascular events in patients who have persistently elevated triglyceride levels
Late 2016
Karyopharm Therapeutics Inc.
Interim analysis update from Phase 2 study of Selinexor (SOPRA study)
Older patients with relapsed/refractory acute myeloid leukemia (AML)
Late 2016
GW Pharmaceuticals PLC
GWPH, GWP.L
Data from phase 2 study of CBDV
Partial-onset epilepsy
Late 2016
Alcobra Ltd.
Data from 2nd phase 3 study of Metadoxine Extended Release (MEASURE)
Adults with ADHD
Late 2016
Alkermes plc
Results from third phase 3 efficacy study of ALKS 5461 ( FORWARD-5)
Major depressive disorder